A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 to Placebo MDI and Open-Label Ventolin® Evohaler in Adult Participants With Asthma

Phase II study, to investigate the therapeutic efficacy and safety of inhaled PT007 (referred to as AS MDI) compared with placebo MDI and open-label Ventolin Evohaler in male and female participants aged 18 to 65 years (inclusive) with asthma.
This study consists of a screening/run-in period, a treatment period, and a follow-up phone call.

开始日期2025-01-06

申办/合作机构

AstraZeneca PLC

NCT06426082 / Not yet recruitingN/AIIT

Deciphering the Molecular and Secretory Functions of a Novel and Unique Brown Adipose Tissue Depot in Women

Type of Study: Clinical Trial
Goal: The goal of this clinical trial is to investigate specific brown and beige fat cells in the dorsocervical area of young, lean adult women.
Participant Population/Health Conditions: The study will involve 40 young, lean adult women.
Main Questions: The main questions this study aims to answer are:
Are there active brown or beige adipocytes in the subcutaneous fat of the dorsocervical area (i.e., iBAT)?
What is the secretory function of these adipocytes?
How do traditional interventions like cold exposure, as well as new approaches like Beta-2 agonist stimulation and exercise, affect the thermogenesis of these fat cells at the cellular and molecular levels?
Participants Will:
Be randomized into one of four groups: thermoneutral exposure, cold exposure, aerobic exercise, or Beta-2 agonist treatment.
Follow their assigned regimen for 4 weeks. Provide tissue samples from the dorsocervical area and abdomen before and after the 4-week intervention.
Undergo analysis of these samples using advanced techniques to understand the presence and activity of brown and beige fat cells.
Comparison Group: Researchers will compare the effects of different interventions (thermoneutral exposure, cold exposure, aerobic exercise, Beta-2 agonist treatment) on the presence and thermogenesis of brown and beige fat cells in the dorsocervical area.

开始日期2024-11-01

申办/合作机构

Universidad de Almería

[+2]

NCT06618105 / Not yet recruiting临床3期

A Prospective, Randomized, Single-dose, Double-blind, Double-dummy, Four-period, Four-treatment Crossover Pivotal Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) (of Macleods Pharmaceuticals Ltd.) to Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) (Distributed by Teva Pharmaceuticals USA, Inc.) in Adult Patients With Stable Mild Asthma

This is a pharmacodynamic bioequivalence bronchoprovocation study using single-dose, double-blind, double-dummy, randomized, study consisting of four study treatments (zero dose [Placebo], E.Q. 90 mcg Base dose of R inhalation aerosol, E.Q. 180 mcg Base dose of R inhalation aerosol, E.Q. 90 mcg Base dose of T inhalation aerosol) and four Periods (Period 1 to Period 4). Randomization procedure at Period 1 will assign any one study treatment to be administered in each Period in a cross-over manner. By the end of Period 4, a subject who completes dosing in all four Periods would have administered all four treatments in the study.
The efficacy variable, post-dose PC20 obtained during each Period is the provocative concentration of the methacholine challenge agent required to reduce the FEV1 by 20% following administration of differing doses of albuterol (or placebo) by inhalation. The 20% reduction in FEV1 is determined as compared to post-saline FEV1 measured before the Placebo or Albuterol administration.
The pharmacodynamic equivalence will be based on the dose-scale method of analysis of the post-dose PC20 If the 90% confidence interval for the relative bioavailability (F) falls within 67.00% -150.00% then it will be considered that pharmacodynamic equivalence is established.

开始日期2024-10-15

申办/合作机构

MacLeods Pharmaceuticals Ltd.

100 项与硫酸沙丁胺醇相关的临床结果

登录后查看更多信息

100 项与硫酸沙丁胺醇相关的转化医学

登录后查看更多信息

100 项与硫酸沙丁胺醇相关的专利（医药）

登录后查看更多信息

10,908

项与硫酸沙丁胺醇相关的文献（医药）

2025-01-01·JOURNAL OF ETHNOPHARMACOLOGY

Evidence to support cultivated fruiting body of Ophiocordyceps sinensis (Ascomycota)'s role in relaxing airway smooth muscle

Article

ETHNOPHARMACOLOGICAL RELEVANCE:

Ophiocordyceps sinensis (O. sinensis) is a genus of Ascomycete fungus that is endemic to the alpine meadows of the Tibetan Plateau and adjoining Himalayas. It has been used traditionally as a tonic to improve respiratory health in ancient China as well as to promote vitality and longevity. Bioactive components found in O. sinensis such as adenosine, cordycepin, 3-deoxyadenosine, L-arginine and polysaccharides have gained increasing interest in recent years due to their antioxidative and other properties, which include anti-asthmatic, antiviral, immunomodulation and improvement of general health.

AIM OF THE STUDY:

This study's primary aim was to investigate the effect of a cultivated fruiting body of O. sinensis strain (OCS02®) on airways patency and the secondary focus was to investigate its effect on the lifespan of Caenorhabditis elegans.

MATERIALS AND METHODS:

A cultivated strain, OCS02®, was employed and the metabolic profile of its cold-water extract (CWE) was analysed through liquid chromatography-mass spectrometry (LC-MS). Organ bath approach was used to investigate the pharmacological properties of OCS02® CWE when applied on airway tissues obtained from adult male Sprague-Dawley rats. The airway relaxation mechanisms of OCS02® CWE were explored using pharmacological tools, where the key regulators in airway relaxation and constriction were investigated. For the longevity study, age-synchronised, pos-1 RNAi-treated wild-type type Caenorhabditis elegans at the L4 stage were utilised for a lifespan assay.

RESULTS:

Various glycopeptides and amino acids, particularly a high concentration of L-arginine, were identified from the LC-MS analysis. In airway tissues, OCS02® CWE induced a significantly greater concentration-dependent relaxation when compared to salbutamol. The relaxation response was significantly attenuated in the presence of NG-Nitro-L-arginine methyl ester (L-NAME), 1H-[1,2,4]oxadiazolo [4,3-a]quinoxalin-1-one (ODQ) and several K⁺ channel blockers. The longevity effect induced by OCS02® CWE (5 mg/mL and above) was observed in C. elegans by at least 17%.

CONCLUSIONS:

These findings suggest that the airway relaxation mechanisms of OCS02® CWE involved cGMP-dependent and cGMP-independent nitric oxide signalling pathways. This study provides evidence that the cultivated strain of OCS02® exhibits airway relaxation effects which supports the traditional use of its wild O. sinensis in strengthening respiratory health.

2024-12-31·EXPERIMENTAL LUNG RESEARCH

Performance of newly developed add-on devices on aerosol delivery in noninvasive ventilated subjects

Article

作者: Mohammad, Mohammad F. ; Madney, Yasmin M. ; Ali, Ahmed M. Abdelhaleem ; Alqarni, Yousef Saeed ; Sarhan, Rania M. ; Alsulami, Fahad T. ; Abdelrahim, Mohamed E. A. ; Rashad, Amal E.

Background: Several techniques had been developed to generate aerosolized medications during noninvasive ventilation (NIV) using variable inhalation methods. This study hypothesized that large spacers were more efficient significantly than small spacers and adapters during NIV. Objective: The main objective of this study was to compare the performance of newly developed spacers with standard T-piece in NIV chronic obstructive pulmonary disease (COPD) subjects. Methods: Sixty COPD subjects requiring NIV were included in this study. A dual-limb circuit was used, and the mode of ventilator was set in spontaneous volume-controlled mode. Dual-limb ventilation circuit, consists of inspiratory-limb and expiratory-limb, is pressure and volume controlled in response to subject expiration providing relatively high resistance to expiratory flow. Two experimental sets were evaluated: the first was introducing two preliminary pressurized metered-dose inhalers (pMDI) puffs before the nebulization of 1 ml of a respirable solution of salbutamol by vibrating mesh nebulizer (VMN) using Minimhal and Combihaler. The second was to only nebulize 1 ml of salbutamol respirable solution by VMN using Combihaler, Minimhal, and standard T-piece. Two urine samples were collected after aerosol delivery: urine sample after 30 min. (USAL0.5) as an indicator of lung deposition and all urine pooled 24 h (USAL24) post-inhalation as an indicator of systemic absorption. The amount of salbutamol extracted from urine samples was assayed by high-performance liquid chromatography. Results: Minimhal + pMDI + VMN delivered a higher percentage of salbutamol 30 min post-inhalation than Minimhal + VMN (p < 0.001). Also, Combihaler + pMDI + VMN delivered a higher percentage of salbutamol 30 min post-inhalation than Combihaler + VMN (p < 0.001). Combihaler + VMN delivered a higher percentage of salbutamol 30 min and 24 h post-inhalation than both Minimhal + VMN and T-piece + VMN (p < 0.001). Standard T-piece delivered the lowest aerosol amount delivered to the lung compared to both spacers (p < 0.05). Conclusions: Introducing two pMDI puffs significantly improved aerosol delivery by both spacers. Combihaler significantly improves aerosol delivery more than Minimhal.

2024-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of budesonide/formoterol SMART therapy versus salmeterol/fluticasone plus as-needed SABA among patients ≥12 years with moderate asthma from the Chinese societal perspective

Article

作者: Zhou, Keruo ; Zuo, Chenyu ; Xuan, Jianwei ; Xie, Xiazhen ; Zhang, Min

OBJECTIVES:

To evaluate the cost-effectiveness of budesonide/formoterol reliever and maintenance therapy compared with salmeterol/fluticasone plus salbutamol as reliever therapy for asthma patients ≥12 years from the societal perspective in China.

METHODS:

A Markov model was developed with three health states (non-exacerbation, exacerbation, and death) with a lifetime horizon. The exacerbation rates were obtained from a prospective cohort study conducted in Chinese asthma patients. Healthcare resources utilization data were estimated based on current clinical asthma management guidelines. Asthma-related mortality, cost input and utility values were derived from public database and literature. Model robustness was assessed with one-way sensitivity and probabilistic sensitivity analyses.

RESULTS:

Compared with salmeterol/fluticasone plus salbutamol, budesonide/formoterol reliever and maintenance therapy led to fewer exacerbation events (13.6 vs. 15.9) and 0.0077 quality-adjusted life years (QALY) gain at an additional cost of ¥196.38 over lifetime. The base case incremental cost-effectiveness ratio (ICER) was ¥25,409.98 per QALY gained. The variables that had most impact on the model output included drug costs and medication adherence. At a willingness-to-pay threshold of ¥257,094/QALY (3 times of gross domestic product per capita in China in 2022), the probability of budesonide/formoterol maintenance and reliever therapy being cost-effective versus salmeterol/fluticasone plus as-needed salbutamol was 83.00%.

CONCLUSION:

From the societal perspective, budesonide/formoterol reliever and maintenance therapy is likely to be a cost-effective option compared with salmeterol/fluticasone plus as-needed salbutamol for Chinese asthma patients ≥12 years.

178

项与硫酸沙丁胺醇相关的新闻（医药）

2024-11-13

·米内网

吸入剂4大集采品种止跌！20亿大品种领跑，恒瑞、正大天晴上榜，齐鲁、普锐特……冲击首仿

精彩内容近日，吸入剂市场波澜再起。四川普锐特药业的富马酸福莫特罗吸入溶液、成都普什制药的吸入用异丙托溴铵溶液等3个产品同日获批。今年以来，吸入剂已有13个品种（78个受理号）获批上市；截至目前，有18个品种（218个品规）过评。米内网数据显示，吸入剂在近年中国公立医疗机构终端销售规模均超过200亿元，2024年上半年同比下滑1.71%。6个国采品种中4个止跌回升，从TOP10来看，吸入用布地奈德混悬液稳居“销冠”宝座，恒瑞医药、正大天晴等上榜。吸入剂有37个品种（177个受理号）报产在审，齐鲁制药、四川普锐特药业等企业冲击首仿。 3款吸入剂同日获批，倍特、健康元、仁合益康领跑过评榜今年10月以来获批上市的吸入剂来源：米内网中国申报进度（MED）数据库日前，国家药监局官网显示，四川普锐特药业的富马酸福莫特罗吸入溶液、成都米子生物医药科技的富马酸福莫特罗吸入溶液、成都普什制药的吸入用异丙托溴铵溶液以新分类报产同日获批，视同过评。今年以来，吸入剂已有13个品种（78个受理号）获批上市，数量超过2023年全年（11个品种、64个受理号）。吸入剂过评情况来源：米内网中国申报进度（MED）数据库截至目前，吸入剂有18个品种（218个品规）过评，其中，吸入用乙酰半胱氨酸溶液、硫酸特布他林雾化吸入用溶液、吸入用异丙托溴铵溶液、吸入用硫酸沙丁胺醇溶液最火，过评企业均有20家及以上。从治疗大类来看，呼吸系统用药过评品种最多，有15个品种（203个品规）。过评5个及以上吸入剂的集团来源：米内网中国申报进度（MED）数据库从集团过评品种数量来看，倍特药业和健康元药业均有9个，仁合益康有7个，湖南华纳大药厂、山东京卫制药、苏州弘森药业各有5个。4个品种独家过评，分别吸入用地氟烷（恒瑞医药）、糠酸莫米松鼻喷雾剂（斯洛文尼亚莱柯）、氮䓬斯汀氟替卡松鼻喷雾剂（盐酸氮䓬斯汀丙酸氟替卡松鼻喷雾剂）（长风药业）、沙美特罗替卡松吸入粉雾剂（健康元药业）。 4大集采品种止跌回升！20亿大品种领跑，恒瑞、正大天晴上榜米内网数据显示，吸入剂在近年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端销售规模均超过200亿元，2024年上半年同比下滑1.71%。从集团TOP20来看，阿斯利康、葛兰素史克、恒瑞医药位居前三，倍特药业凭借超过30%的增速晋身到前十之列，正大制药、仁合益康、欧加农制药增速均超过20%。从治疗大类来看，呼吸系统用药占据主导。 2024年上半年中国公立医疗机构终端吸入剂产品TOP10来源：米内网中国公立医疗机构药品终端竞争格局吸入剂产品的市场集中度较高，TOP10合计市场份额占比超过70%。其中，吸入用布地奈德混悬液以超过20亿元销售额领跑，吸入用七氟烷、布地奈德福莫特罗吸入粉雾剂(Ⅱ)、吸入用乙酰半胱氨酸溶液均超过10亿元。 4个止跌回升的集采品种近年中国公立医疗机构终端销售额增速来源：米内网中国公立医疗机构药品终端竞争格局目前，吸入剂已有6个品种被纳入集采，其中5个在产品TOP20之列。从增速来看，第四批的吸入用硫酸沙丁胺醇溶液，第五批的吸入用布地奈德混悬液、吸入用异丙托溴铵溶液、吸入用复方异丙托溴铵溶液4个集采品种止跌回升，2024年上半年分别同比增长0.57%、9.20%、18.09%、4.43%，第七批的硫酸特布他林雾化吸入用溶液和第九批的盐酸左沙丁胺醇雾化吸入溶液分别同比下滑30.28%、7.94%。吸入用布地奈德混悬液在经历集采冲击后仍稳居“销冠”宝座，2024年上半年同比增长9.20%，虽然阿斯利康的市场份额最大，但占比快速下滑，从2021年超过70%到2024年上半年不足40%；正大天晴药业集团、四川普锐特药业、长风药业等4家中标的国内企业则快速扩容。目前，吸入用布地奈德混悬液有8家企业拥有生产批文，其中，浙江福瑞喜药业、河北仁合益康药业、南京力成药业3家在今年获批；此外，鲁南贝特制药、湖南醇健制药科技、浙江赛默制药等10家以仿制4类报产在审。 2024年上半年中国公立医疗机构终端吸入剂品牌TOP10来源：米内网中国公立医疗机构药品终端竞争格局品牌TOP10中，阿斯利康的布地奈德福莫特罗吸入粉雾剂(Ⅱ)和吸入用布地奈德混悬液、上海恒瑞医药的吸入用七氟烷位居前三，阿斯利康的布地奈德福莫特罗吸入粉雾剂(Ⅱ)是唯一一个销售额超10亿元的品牌。从增速来看，4个品牌为正增长，正大天晴药业集团的吸入用布地奈德混悬液增速最快，超过50%。从企业品牌数量来看，阿斯利康有3个上榜，其次是健康元药业集团有2个上榜。吸入剂新品蜂拥而至，齐鲁、普锐特……冲击首仿 11月13日，四川普锐特药业的异丙托溴铵吸入气雾剂、江苏大红鹰恒顺药业的富马酸福莫特罗吸入溶液、苏州欧米尼医药的噻托溴铵吸入粉雾剂均以仿制4类同日报产获CDE受理。截至目前，吸入剂有37个品种（177个受理号）报产在审，富马酸福莫特罗吸入溶液最抢手，有21家，吸入用乙酰半胱氨酸溶液、盐酸丙卡特罗吸入溶液、盐酸左沙丁胺醇雾化吸入溶液、吸入用布地奈德混悬液4个产品有10家及以上企业报产在审。从企业数量来看，四川普锐特药业、葫芦娃药业和康恩贝均有4个品种报产在审，海南斯达制药、山西达因儿童制药、石家庄四药等各有3个品种报产在审。国内无仿制药获批且报产在审的吸入剂来源：米内网中国申报进度（MED）数据库此外，丙酸氟替卡松鼻喷雾剂、布地奈德福莫特罗吸入气雾剂、吸入用盐酸溴己新溶液、吸入用丙酸倍氯米松混悬液等吸入剂国内暂无仿制药获批，齐鲁制药、四川普锐特药业、北京双鹭药业等企业有望拿下首仿。资料来源：国家药监局官网、米内网数据库等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准医药出海带量采购

2024-11-12

·PRNewswire

Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight

After over a decade without notable progress in treating chronic obstructive pulmonary disease, patients with this ongoing condition now have two new treatment options, with more expected in the future. Regeneron and Sanofi recently revealed that the FDA has expanded the approved uses of their widely successful drug DUPIXENT to include COPD treatment. This marks the drug's sixth approved indication in the US, following its first approval seven years ago for atopic dermatitis. LAS VEGAS, Nov. 12, 2024 /PRNewswire/ -- Chronic obstructive pulmonary disease (COPD) is a progressive lung condition characterized by obstructed airflow, making breathing difficult. It primarily encompasses two main conditions: chronic bronchitis and emphysema, often coexisting. COPD typically develops due to long-term exposure to irritants such as cigarette smoke, air pollution, or occupational dust. As per DelveInsight analysis, the diagnosed prevalent population of COPD in the 7MM was around 44 million in 2023. These cases of COPD in the 7MM are expected to increase at a significant CAGR of 1.4% throughout the study period (2020–2034). As per the estimates, the majority of cases of COPD are in females as compared to males, in the US. But in EU4 and the UK, and Japan the diagnosed cases of males represent the majority of the cases. Overall, in the 7MM, females are predominantly high in number. In 2023, the US had around 3 million, 9 million, 5 million, and 1 million cases of GOLD 1, GOLD 2, GOLD 3, and GOLD 4, respectively based on the severity of airflow limitation. Estimates suggest that airflow limitation was higher in GOLD 2 severity. Various types of medications are used to manage COPD symptoms and complications, including bronchodilators, which help relax the muscles around the airways. This relaxation opens the airways and makes breathing easier. Most bronchodilators are administered via an inhaler. In more severe cases, the inhaler may also contain steroids to reduce inflammation. Some commonly used short-acting and long-acting bronchodilators for COPD management include Albuterol (ProAir HFA, Ventolin HFA, and others), Ipratropium (Atrovent HFA), Levalbuterol (Xopenex), Aclidinium (Tudorza Pressair), Arformoterol (Brovana), and Formoterol (Perforomist). In the LABA category, medications such as Striverdi Respimat, Arcapta/Onbrez, Serevent, and Brovana are included, while the LAMA class features drugs like Spiriva (available as Spiriva HandiHaler and Spiriva Respimat), Tudorza Pressair, Incruse Ellipta, Yupelri, Seebri Neohaler, and Lonhala Magnair. Since the generic version of Brovana was approved in April 2020, its market share has declined. Additionally, Arcapta Neohaler, Seebri Neohaler, and Utibron Neohaler were discontinued in the US in March 2020, which means they no longer contribute to market size. Patients who do not respond to single therapies are often prescribed double or triple therapy. Among the double therapies, the LABA+ICS combination is widely recommended, with drugs such as Symbicort, Breo Ellipta, and Advair. There are also LABA+LAMA combinations, including Anoro Ellipta, Stiolto Respimat, and Bevespi Aerosphere. In July 2020, the US FDA approved AstraZeneca's BREZTRI AEROSPHERE for the maintenance treatment of patients with COPD. Additionally, in October 2020, TRIXEO AEROSPHERE (a combination of formoterol fumarate, glycopyrronium bromide, and budesonide) received marketing authorization in the EU for the maintenance treatment of adult patients with moderate to severe COPD who are not adequately controlled by either a combination of an ICS and LABA or a LABA and LAMA. Currently, two triple combination therapies are available in the US: BREZTRI and TRELEGY ELLIPTA. Learn more about the FDA-approved COPD drugs @ Drugs for COPD Treatment Recently, Sanofi/Regeneron Pharmaceuticals' DUPIXENT added one more jewel to its crown by getting a label expansion nod for COPD from the FDA, EU, and NMPA. DUPIXENT's approval as the first targeted therapy for COPD represents a significant advancement in the treatment landscape for the disease. Unlike conventional treatments, which largely aim to manage symptoms, DUPIXENT specifically targets the IL-4 and IL-13 pathways linked to type 2 inflammation, a key driver in a subset of COPD patients. This precision in targeting allows for a more tailored treatment, especially for patients with elevated eosinophils, who often experience more frequent exacerbations and worse outcomes. The Phase III BOREAS trial demonstrated that patients treated with DUPIXENT experienced a 30% reduction in moderate-to-severe exacerbations over 52 weeks, significant improvements in lung function, and enhanced quality of life. By Week 52, those on DUPIXENT had improved prebronchodilator FEV1 by 160 mL compared to 77 mL in the placebo group. DUPIXENT was also well-tolerated, with a low frequency of adverse events. These results suggest that DUPIXENT could drastically shift COPD management by reducing exacerbations, improving lung function, and offering a safer, targeted therapy for patients with type 2 inflammation. To know more about COPD treatment options, visit @ New Treatment for COPD The chronic obstructive pulmonary disease pipeline possesses potential drugs in mid-stage developments to be launched in the near future. Itepekimab (Sanofi/Regeneron Pharmaceuticals), Benralizumab (AstraZeneca), Tezepelumab (Amgen/AstraZeneca), Mepolizumab (GSK), and others shall further create a positive impact on the market. Discover which therapies are expected to grab major COPD market share @ COPD Market Report Itepekimab is a fully human monoclonal antibody that targets interleukin-33 (IL-33), a protein involved in both type 1 and type 2 inflammation. The drug is administered via subcutaneous injection. Preclinical studies demonstrated that REGN3500 effectively inhibited several markers of both inflammatory types. Regeneron and Sanofi are investigating REGN3500 in diseases related to respiratory and dermatological inflammation. Currently, REGN3500 is in a Phase III clinical trial for COPD and was developed using Regeneron's VelocImmune technology, which produces optimized fully human antibodies. The development is part of a global collaboration between Regeneron and Sanofi. FASENRA (benralizumab) is a humanized recombinant monoclonal antibody of the IgG1k immunoglobulin type that selectively targets the alpha chain of the interleukin 5 receptor (IL-5R) found on eosinophils and basophils. It prevents IL-5 from binding and stops the hetero-oligomerization of the IL-5R's alpha and beta subunits, thereby inhibiting signal transduction. Additionally, it is an afucosylated IgG, which enhances its affinity for the FcγRIIIα receptor on natural killer cells, macrophages, and neutrophils. Approved by the FDA in November 2017 for severe eosinophilic asthma, benralizumab was developed by MedImmune, AstraZeneca's global biologics R&D division. The company is currently conducting Phase III clinical trials for FASENRA as a treatment for COPD. TEZSPIRE (tezepelumab), a pioneering human monoclonal antibody created by Amgen and AstraZeneca, has shown considerable therapeutic potential for various respiratory conditions. Originally intended for treating COPD, TEZSPIRE has yielded encouraging results in decreasing moderate-to-severe exacerbations in patients with high blood eosinophil counts. Recent findings from the Phase IIa COURSE Trial, unveiled at the ATS 2024 conference, underscored TEZSPIRE's effectiveness in minimizing COPD exacerbations among patients with different eosinophil levels. Mepolizumab is currently undergoing Phase III clinical trials for COPD, particularly in patients with frequent exacerbations and elevated eosinophil levels. It is available as an injectable solution and a powder for reconstitution for subcutaneous administration. The IL-5 receptor complex activates several signaling pathways that lead to the release of cytokines, neuromediators, chemokines, and various kinases, which facilitate eosinophil differentiation, proliferation, recruitment, and degranulation. Mepolizumab works by inhibiting the formation of the IL-5 receptor complex, thereby preventing eosinophil activation. This disruption affects normal eosinophil maturation and function, leading to decreased eosinophilic airway inflammation and reduced eosinophil survival. Discover more about drugs for COPD in development @ COPD Clinical Trials The anticipated launch of these emerging therapies for COPD are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the COPD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for COPD in the 7MM is expected to grow from USD 16 billion in 2023 with a significant CAGR of 5% by 2034. This growth is mainly driven by the rise in the number of prevalent cases of COPD, ongoing clinical research, and better diagnostic tools that might improve the prognosis of the disease. DelveInsight's latest published market report titled as Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the COPD country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The COPD market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases of COPD Subtype-specific Diagnosed Prevalent Cases of COPD Gender-specific Diagnosed Prevalent Cases of COPD Age-specific Diagnosed Prevalent Cases of COPD Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM COPD market. Highlights include: 11-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this COPD market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the COPD market. Also, stay abreast of the mitigating factors to improve your market position in the COPD therapeutic space. Related Reports Chronic Obstructive Pulmonary Disease Pipeline Chronic Obstructive Pulmonary Disease Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key COPD companies, including Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Foresee Pharmaceuticals, Amgen, Organicell Regenerative Medicine, Arrowhead Pharmaceuticals, ProterixBio, RS BioTherapeutics, MitoRx, C4X Discovery, Respiratorius, ARK biosciences, Incannex, GNI Pharma, Celon pharma, Alveolus Bio, Kinaset therapeutics, Landos Biopharma, Parion Sciences, KeyMed Biosciences, Bioneer corporation, AlgiPharma, Palobiofarma, Dimerix Bioscience, Glenmark Pharmaceuticals, among others. Asthma Market Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc. , among others. Asthma Pipeline Asthma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key asthma companies, including Jiangsu Hengrui Medicine, GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., ARS Pharmaceuticals, Sanofi, Zura Bio Ltd., AstraZeneca, EURRUS Biotech GmbH, T-Balance Therapeutics GmbH, Gossamer Bio, Aldeyra Therapeutics, Inc., Trio Medicines, Janssen Research & Development, Arrowhead Pharmaceuticals, Hoffman-La-Roche, GlaxoSmithKline, Biohaven Pharmaceutical, TAK-Circulator Co., Shanghai Hengrui Pharmaceutical, among others. Acute Respiratory Distress Syndrome Market Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ARDS companies, including MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果上市批准临床3期临床2期

2024-11-03

·信狐药迅

恒瑞自免夫那奇珠单抗新适应症强直性脊柱炎、西安葛蓝新通抗乙肝1类新药帕拉德福韦获批上市| 新获批（10.28-11.3）

每周药品注册获批数据，分门别类呈现，一目了然。(10.28-11.3）新药上市申请药品名称企业注册分类受理号甲磺酸帕拉德福韦片西安葛蓝新通制药有限公司1CXHS2300049夫那奇珠单抗注射液苏州盛迪亚生物医药有限公司1CXSS2400019 新药临床申请药品名称企业注册分类受理号西奥罗尼胶囊深圳微芯生物科技股份有限公司1CXHL2400870西奥罗尼胶囊深圳微芯生物科技股份有限公司1CXHL2400869注射用RAB001中山莱博瑞辰生物医药有限公司1CXHL2400853洛布替尼片广州麓鹏制药有限公司1CXHL2400851洛布替尼片广州麓鹏制药有限公司1CXHL2400850HRS-6208胶囊山东盛迪医药有限公司1CXHL2400849HRS-6208胶囊山东盛迪医药有限公司1CXHL2400848KFA115Novartis Pharma AG1JXHL2400206KFA115Novartis Pharma AG1JXHL2400205KFA115Novartis Pharma AG1JXHL2400204KFA115Novartis Pharma AG1JXHL2400203Sonrotoclax薄膜包衣片百济神州(苏州)生物科技有限公司1CXHL2400843Sonrotoclax薄膜包衣片百济神州(苏州)生物科技有限公司1CXHL2400842Sonrotoclax薄膜包衣片百济神州(苏州)生物科技有限公司1CXHL2400841Sonrotoclax薄膜包衣片百济神州(苏州)生物科技有限公司1CXHL2400840TQB3909片正大天晴药业集团南京顺欣制药有限公司1CXHL2400847TQB3909片正大天晴药业集团南京顺欣制药有限公司1CXHL2400846HRS-5632注射液福建盛迪医药有限公司1CXHL2400839ARD-885片科辉智药(深圳)新药研究中心有限公司1CXHL2400834ARD-885片科辉智药(深圳)新药研究中心有限公司1CXHL2400833HRS-6209胶囊江苏恒瑞医药股份有限公司1CXHL2400831HRS-6209胶囊江苏恒瑞医药股份有限公司1CXHL2400830HRS-6209胶囊江苏恒瑞医药股份有限公司1CXHL2400829HRS-6209胶囊江苏恒瑞医药股份有限公司1CXHL2400828RDSY1801肠溶胶囊上海德建聪和生物医药科技有限公司1CXHL2400818RDSY1801肠溶胶囊上海德建聪和生物医药科技有限公司1CXHL2400817RDSY1801肠溶胶囊上海德建聪和生物医药科技有限公司1CXHL2400816YKYY015注射液杭州天龙药业有限公司1CXHL2400819NH600001乳状注射液江苏恩华药业股份有限公司1CXHL2400780BCM684口崩片上海云晟研新生物科技有限公司2.2CXHL2400852DT-PR2215西安远大科创医药科技有限公司2.2CXHL2400837DT-PR2215西安远大科创医药科技有限公司2.2CXHL2400836DT-PR2215西安远大科创医药科技有限公司2.2CXHL2400835吸入用H057上海汇伦医药股份有限公司2.2;2.4CXHL2400838Lazertinib片Janssen Research & Development, LLC2.4JXHL2400207Nivolumab/Relatlimab固定剂量复方注射液Bristol-Myers Squibb Company1JXSL2400154CM512注射液康诺亚生物医药科技(成都)有限公司1CXSL2400558CVL006 注射液甫康(上海)健康科技有限责任公司1CXSL2400555AZD5492AstraZeneca AB1JXSL2400149LAT010注射液徕特康(苏州)生物制药有限公司1CXSL2400551重组全人源抗PCSK9单抗注射液信立泰(成都)生物技术有限公司1CXSL2400547重组抗BDCA2人源化单克隆抗体注射液三生国健药业(上海)股份有限公司1CXSL2400545重组抗BDCA2人源化单克隆抗体注射液三生国健药业(上海)股份有限公司1CXSL2400544SHR-2173注射液广东恒瑞医药有限公司1CXSL2400546RC198注射液荣昌生物制药(烟台)股份有限公司1CXSL2400542ALPN-303注射液Alpine Immune Sciences, Inc.1JXSL2400147ZM001注射液厦门再妙生物科技有限公司1CXSL2400515YFQLXB-UC01注射液山东省齐鲁细胞治疗工程技术有限公司1CXSL2400516Amivantamab注射液(皮下注射)Janssen Research & Development, LLC2.1JXSL2400156Amivantamab注射液(皮下注射)Janssen Research & Development, LLC2.1JXSL2400155Amivantamab注射液(皮下注射)Janssen Research & Development, LLC2.1JXSL2400153Amivantamab注射液(皮下注射)Janssen Research & Development, LLC2.1JXSL2400152Amivantamab注射液(皮下注射)Janssen Research & Development, LLC2.1JXSL2400151Amivantamab注射液(皮下注射)Janssen Research & Development, LLC2.1JXSL2400150 仿制药申请药品名称企业注册分类受理号乙酰半胱氨酸注射液苏州弘森药业股份有限公司3CYHS2401207乙酰半胱氨酸注射液北京康蒂尼药业股份有限公司3CYHS2400105乙酰半胱氨酸注射液杭州云柏医药科技有限公司3CYHS2400081富马酸福莫特罗吸入溶液四川普锐特药业有限公司3CYHS2301873盐酸多巴胺注射液南京康川济医药科技有限公司3CYHS2301483头孢丙烯干混悬剂广州白云山医药集团股份有限公司白云山制药总厂3CYHS2301353硫酸沙丁胺醇注射液浙江华海药业股份有限公司3CYHS2301128依折麦布瑞舒伐他汀钙片(Ⅲ)北京韩美药品有限公司3CYHS2301014依折麦布瑞舒伐他汀钙片(Ⅱ)北京韩美药品有限公司3CYHS2301013依折麦布瑞舒伐他汀钙片(Ⅰ)北京韩美药品有限公司3CYHS2301012马来酸噻吗洛尔滴眼液沈阳兴齐眼药股份有限公司3CYHS2300927注射用左亚叶酸钙四川百利药业有限责任公司3CYHS2300895注射用盐酸罗沙替丁醋酸酯山西普德药业有限公司3CYHS2300546注射用盐酸罗沙替丁醋酸酯重庆药友制药有限责任公司3CYHS2300089马来酸噻吗洛尔滴眼液江苏远恒药业有限公司3CYHS2202154国;CYHS2202154马来酸噻吗洛尔滴眼液江苏远恒药业有限公司3CYHS2202153国;CYHS2202153地奈德乳膏海思科制药(眉山)有限公司3CYHS2202104国;CYHS2202104钠钾镁钙葡萄糖注射液宜昌人福药业有限责任公司3CYHS2201956国;CYHS2201956氨溴特罗口服溶液呋欧医药科技(湖州)有限公司3CYHS2200731脂肪乳(10)/氨基酸(15)/葡萄糖(20)注射液山东齐都药业有限公司4CYHS2402918黄体酮阴道缓释凝胶福建科瑞药业有限公司4CYHS2400059氧开鲁县兴远气体有限公司4CYHS2303674氧贵州利得利气体有限公司4CYHS2303662黄体酮阴道缓释凝胶江苏万高药业股份有限公司4CYHS2303533黄体酮阴道缓释凝胶广东众生药业股份有限公司4CYHS2303531注射用阿糖胞苷四川百利药业有限责任公司4CYHS2303254盐酸纳呋拉啡口腔崩解片南京海纳制药有限公司4CYHS2303178利格列汀片江苏德源药业股份有限公司4CYHS2302615注射用磷酸特地唑胺丽珠集团丽珠制药厂4CYHS2302463富马酸卢帕他定片浙江普利药业有限公司4CYHS2302416硝苯地平控释片青岛黄海制药有限责任公司4CYHS2302410硫酸羟氯喹片浙江杭康药业有限公司4CYHS2302405富马酸福莫特罗吸入溶液成都米子生物医药科技有限公司4CYHS2302404羟苯磺酸钙胶囊江苏德源药业股份有限公司4CYHS2302401阿戈美拉汀片山东京卫制药有限公司4CYHS2302383比索洛尔氨氯地平片江西施美药业股份有限公司4CYHS2302271氟哌噻吨美利曲辛片植恩生物技术股份有限公司4CYHS2302252注射用氯诺昔康华东医药(西安)博华制药有限公司4CYHS2302216苯甲酸阿格列汀片宁波美诺华天康药业有限公司4CYHS2302176苯甲酸阿格列汀片宁波美诺华天康药业有限公司4CYHS2302175恩曲他滨丙酚替诺福韦片(II)正大天晴药业集团股份有限公司4CYHS2302018注射用胸腺法新成都地奥制药集团有限公司4CYHS2302020尼莫地平注射液重庆莱美药业股份有限公司4CYHS2301948普伐他汀钠片南京道群医药研发有限公司4CYHS2301963普伐他汀钠片南京道群医药研发有限公司4CYHS2301962盐酸达泊西汀片苏州海景医药科技有限公司4CYHS2301927盐酸达泊西汀片苏州海景医药科技有限公司4CYHS2301926氧(液态)龙陵县永盛气体有限公司4CYHS2301891氧龙陵县永盛气体有限公司4CYHS2301890奥卡西平片合肥英太制药有限公司4CYHS2301856奥卡西平片合肥英太制药有限公司4CYHS2301855帕立骨化醇注射液华润双鹤药业股份有限公司4CYHS2301845氧百色市博翔气体有限公司4CYHS2301806注射用氯诺昔康浙江华海药业股份有限公司4CYHS2301784酒石酸溴莫尼定滴眼液苏州欧康维视生物科技有限公司4CYHS2301741左氧氟沙星滴眼液苏州欧康维视生物科技有限公司4CYHS2301703间苯三酚注射液四川新斯顿制药股份有限公司4CYHS2301675阿戈美拉汀片四川国为制药有限公司4CYHS2301660他达拉非片湘北威尔曼制药股份有限公司4CYHS2301655恩格列净片山东新时代药业有限公司4CYHS2301629磷酸奥司他韦胶囊海南亚洲制药股份有限公司4CYHS2301610依巴斯汀片上海理想制药有限公司4CYHS2301529盐酸帕罗西汀肠溶缓释片北大医药股份有限公司4CYHS2301522盐酸乌拉地尔注射液安徽海斯美医药有限公司4CYHS2301492盐酸乌拉地尔注射液安徽海斯美医药有限公司4CYHS2301491注射用盐酸地尔硫䓬安徽省先锋制药有限公司4CYHS2301481间苯三酚注射液河北创健药业有限公司4CYHS2301456吸入用异丙托溴铵溶液成都普什制药有限公司4CYHS2301391盐酸托莫西汀口服溶液重庆希尔安药业有限公司4CYHS2301202注射用头孢他啶阿维巴坦钠海口市制药厂有限公司4CYHS2301182阿戈美拉汀片江苏安必生制药有限公司4CYHS2301079氧(液体)陕西亚泰气体有限责任公司4CYHS2301064依折麦布片北京百奥药业有限责任公司4CYHS2301020盐酸莫西沙星滴眼液乐普药业股份有限公司4CYHS2300920玻璃酸钠滴眼液上海阿尔福斯医药科技有限公司4CYHS2300875玻璃酸钠滴眼液上海阿尔福斯医药科技有限公司4CYHS2300874波生坦片北京四环科宝制药股份有限公司4CYHS2300826二甲双胍恩格列净片(VI)浙江恒研医药科技有限公司4CYHS2300816缬沙坦氢氯噻嗪片宁波科尔康美诺华药业有限公司4CYHS2300751泊沙康唑注射液江苏正大丰海制药有限公司4CYHS2300570普瑞巴林胶囊福建省宝诺医药研发有限公司4CYHS2300563普瑞巴林胶囊福建省宝诺医药研发有限公司4CYHS2300562磷酸西格列汀片山东新时代药业有限公司4CYHS2300440磷酸西格列汀片山东新时代药业有限公司4CYHS2300439磷酸西格列汀片山东新时代药业有限公司4CYHS2300438复方聚乙二醇电解质散(III)海南允鼎医药科技有限公司4CYHS2300259左卡尼汀口服溶液北京诚济康荣生物科技有限公司4CYHS2300178醋酸加尼瑞克注射液扬子江药业集团江苏紫龙药业有限公司4CYHS2300151利丙双卡因乳膏湖南九典制药股份有限公司4CYHS2300054马来酸阿法替尼片江苏华阳制药有限公司4CYHS2300015国;CYHS2300015马来酸奈拉替尼片江苏奥赛康药业有限公司4CYHS2202006国;CYHS2202006利丙双卡因乳膏呋欧医药科技(湖州)有限公司4CYHS2201242国;CYHS2201242枸橼酸坦度螺酮片沈阳华泰药物研究有限公司4CYHS2200648国;CYHS2200648盐酸卡利拉嗪胶囊成都奥邦药业有限公司3CYHL2400169盐酸卡利拉嗪胶囊成都奥邦药业有限公司3CYHL2400168利多卡因丙胺卡因气雾剂山东百诺医药股份有限公司3CYHL2400165十四烷基硫酸钠注射液上海上药第一生化药业有限公司3CYHL2400167十四烷基硫酸钠注射液上海上药第一生化药业有限公司3CYHL2400166帕立骨化醇软胶囊南京海融医药科技股份有限公司3CYHL2400164盐酸毛果芸香碱滴眼液北京福元医药股份有限公司3CYHL2400163 进口申请药品名称企业注册分类受理号匹妥布替尼片Eli Lilly Nederland B.V.5.1JXHS2300111匹妥布替尼片Eli Lilly Nederland B.V.5.1JXHS2300110盐酸托莫西汀胶囊Nichi-Iko Pharmaceutical Co., Ltd.5.2JYHS2300102盐酸托莫西汀胶囊Nichi-Iko Pharmaceutical Co., Ltd.5.2JYHS2300101盐酸托莫西汀胶囊Nichi-Iko Pharmaceutical Co., Ltd.5.2JYHS2300100盐酸厄洛替尼片Dr. Reddy's Laboratories Limited5.2JYHS2300045盐酸厄洛替尼片Dr. Reddy's Laboratories Limited5.2JYHS2300044沙库巴曲缬沙坦钠片Dr. Reddy's Laboratories Limited5.2JYHS2300018沙库巴曲缬沙坦钠片Dr. Reddy's Laboratories Limited5.2JYHS2300017 中药相关申请无注：橙色字体部分结论为不批准或收到通知件；

申请上市上市批准

100 项与硫酸沙丁胺醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	硫酸沙丁胺醇	R03CC02 R03AC02	DB01001

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
运动诱发哮喘	美国	Schering Corp.	1981-05-01
支气管痉挛	美国	Schering Corp.	1981-05-01
气道阻塞	日本	GSK Plc	1973-01-13
哮喘	日本	GSK Plc	1973-01-13
支气管炎	日本	GSK Plc	1973-01-13
肺气肿	日本	GSK Plc	1973-01-13
肺结核	日本	GSK Plc	1973-01-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性哮喘	申请上市	加拿大	益得生物科技股份有限公司	-
持续性哮喘	临床3期	美国	Teva Branded Pharmaceutical Products R&D, Inc.	2012-12-01
儿童哮喘	临床3期	美国	Teva Branded Pharmaceutical Products R&D, Inc.	2006-06-10
慢性阻塞性肺疾病	临床3期	美国	GSK Plc	2004-09-01
慢性阻塞性肺疾病	临床3期	波多黎各	GSK Plc	2004-09-01
特发性肺纤维化	临床1期	英国	GSK Plc	2012-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03199976 (CTgov)	临床4期	哮喘 \| 气道阻塞 \| 喘息性支气管炎	80	Tiotropium Bromide+salbutamol (Tiotropium Bromide & Salbutamol)	衊膚繭醖鏇選築鑰選鹽(鬱願觸範夢壓淵憲範築) = 網製糧觸網壓鹹蓋顧範鹽鹹觸窪鹹鹽簾範夢醖 (鹹鹽觸鑰窪鏇選鬱窪鹽, 簾壓衊艱夢積遞顧網築 ~ 鑰簾簾鑰襯鹽齋廠憲遞) 更多	-	2024-09-19
				salbutamol+Fluticasone Propionate (Fluticasone Propionate & Salbutamol)	衊膚繭醖鏇選築鑰選鹽(鬱願觸範夢壓淵憲範築) = 鹹醖鏇構鹽構鬱鬱積夢鹽鹹觸窪鹹鹽簾範夢醖 (鹹鹽觸鑰窪鏇選鬱窪鹽, 餘範窪蓋膚觸襯網顧鬱 ~ 窪齋餘網觸簾壓構構壓) 更多
ATS2024	N/A	-	-	Albuterol pMDI alone	積鏇鏇糧鹹醖襯選遞網(壓鹹廠積繭選廠廠鏇鬱) = 襯觸蓋糧選鹹網鏇繭範積蓋願壓鏇積壓糧觸蓋 (範壓鑰願網夢窪艱鑰願, 32 ~ 39)	-	2024-05-19
				Albuterol pMDI + VHC	積鏇鏇糧鹹醖襯選遞網(壓鹹廠積繭選廠廠鏇鬱) = 構觸顧顧築膚鏇鹽淵鏇積蓋願壓鏇積壓糧觸蓋 (範壓鑰願網夢窪艱鑰願, 1.1 ~ 1.7)
NCT02508311 (CTgov)	临床4期	呼吸麻痹 \| 脊髓损伤	1	Oral Albuterol Extended Release (Active Oral Beta-2)	夢鹽選願構鬱鑰製積壓(淵願鏇願襯醖繭醖選壓) = 衊繭繭壓願壓蓋鑰膚網構構願艱觸壓憲醖餘觸 (積艱廠膚鬱餘鑰顧製襯, 鹹廠選選鬱鏇醖膚鹹衊 ~ 製鏇繭壓衊選鹹蓋鹽鹹) 更多	-	2024-05-07
				Placebo (Placebo)	夢鹽選願構鬱鑰製積壓(淵願鏇願襯醖繭醖選壓) = 蓋餘築糧齋遞壓築構襯構構願艱觸壓憲醖餘觸 (積艱廠膚鬱餘鑰顧製襯, 願夢夢廠築選壓廠淵糧 ~ 願網製簾鹽蓋艱艱獵鑰) 更多
NCT00521222 (ARGARG, CTgov)	N/A	哮喘	90	Albuterol HFA+Ipratropium HFA+Fluticasone (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA)	遞鹽構構醖鑰鹽獵製醖(蓋窪獵壓鏇淵餘鑰遞憲) = 膚膚膚衊糧選鬱觸積遞鏇積網構顧窪襯憲觸鑰 (製餘構鏇壓醖膚選鬱選, 衊獵遞壓齋鬱積築膚鹹 ~ 獵構齋鬱壓夢製憲壓顧) 更多	-	2023-04-21
				Albuterol HFA+Ipratropium HFA+Fluticasone (Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA)	遞鹽構構醖鑰鹽獵製醖(蓋窪獵壓鏇淵餘鑰遞憲) = 夢鹽艱餘糧壓鑰壓鏇齋鏇積網構顧窪襯憲觸鑰 (製餘構鏇壓醖膚選鬱選, 壓襯廠鹹築觸蓋夢鏇願 ~ 製鹽艱窪艱積夢齋遞遞) 更多
NCT04677959 (CONNECT2, CTgov)	临床4期	哮喘	427	Albuterol+Fluticasone propionate/salmeterol (FS)	願簾鏇願構遞廠簾鬱窪(製醖願艱網遞鹽鹽淵鬱) = 鏇醖選襯衊築網餘齋夢鹹顧構鏇壓淵製衊廠醖 (壓觸獵艱願鏇觸醖憲壓, 膚鑰鏇獵選鑰繭襯淵願 ~ 網夢蓋顧膚選範糧廠積) 更多	-	2023-03-14
NCT03890666 (CONNECT1, CTgov)	临床4期	哮喘	333	albuterol (Concurrent Control (CC))	淵鬱膚壓鹹醖鹽積齋廠(鏇衊餘壓鏇餘繭鏇憲糧) = 願壓繭壓選糧觸鏇窪憲衊廠觸鹹鏇遞襯製鏇獵 (獵醖鹽壓淵憲鑰選積廠, 窪積淵簾糧選淵餘鏇壓 ~ 簾簾願繭觸窪糧廠餘遞) 更多	-	2022-10-27
				Albuterol eMDPI DS (Digital System (DS))	淵鬱膚壓鹹醖鹽積齋廠(鏇衊餘壓鏇餘繭鏇憲糧) = 廠繭鑰繭選選鹹築夢構衊廠觸鹹鏇遞襯製鏇獵 (獵醖鹽壓淵憲鑰選積廠, 衊製選構夢構壓築遞鑰 ~ 餘築淵鬱廠範鑰鏇鹹艱) 更多
ERS2022	N/A	慢性阻塞性肺疾病	58	Salbutamol	鑰積積淵淵廠選鑰鑰夢(廠簾窪醖窪鹽齋糧獵壓) = 積齋鏇醖範製鏇鹹獵鑰繭夢鏇窪鏇顧壓網選齋 (廠遞夢窪鏇憲憲簾夢築 ) 更多	积极	2022-09-04
				Salbutamol	鑰積積淵淵廠選鑰鑰夢(廠簾窪醖窪鹽齋糧獵壓) = 襯鹽壓積餘鹹鹹顧糧願繭夢鏇窪鏇顧壓網選齋 (廠遞夢窪鏇憲憲簾夢築 ) 更多
ERS2022	N/A	心血管疾病	-	Salbutamol	鏇網襯鑰繭鬱膚餘觸齋(繭鹽醖製鹽鹹簾糧鹽衊) = Salbutamol was associated with a very common risk of palpitations or tachycardia, suggesting more clinical vigilance 衊憲鹽艱簾餘膚齋繭窪 (鹽憲鑰範鹽網積艱鑰遞 )	不佳	2022-09-04
NCT00530062 (CTgov)	临床4期	哮喘	49	Albuterol-HFA-BAI (Albuterol-HFA-BAI)	簾淵蓋憲範糧構鏇艱蓋(遞糧糧蓋醖淵淵構鬱憲) = 膚艱壓廠糧築鏇選鏇齋構鏇觸構範壓襯壓網蓋 (膚鬱廠鏇鹹遞夢鹹窪衊, 鹽獵簾鬱範顧鹽顧窪鹹 ~ 窪鏇構鑰醖糧顧醖網鏇) 更多	-	2022-08-31
				Albuterol-HFA-MDI (Albuterol-HFA-MDI)	簾淵蓋憲範糧構鏇艱蓋(遞糧糧蓋醖淵淵構鬱憲) = 鹹獵鏇遞鹽繭淵糧範餘構鏇觸構範壓襯壓網蓋 (膚鬱廠鏇鹹遞夢鹹窪衊, 窪糧選鹹壓觸鑰構鏇鹽 ~ 製鹽淵鹽願範積鬱繭構) 更多
NCT00308685 (CTgov)	临床3期	儿童哮喘	95	Albuterol (Albuterol-HFA-BAI)	襯簾選築網遞蓋獵夢選(夢鹽窪顧獵糧鹽憲憲獵) = 夢鹹觸簾膚選糧網廠範獵淵願鹹繭淵鑰鑰選鑰 (艱餘鹹膚範網壓鹽膚憲, 製糧壓憲襯襯憲鹽觸醖 ~ 鹹積膚簾壓範範蓋顧鑰) 更多	-	2022-02-24
				Placebo (Placebo-HFA-BAI)	襯簾選築網遞蓋獵夢選(夢鹽窪顧獵糧鹽憲憲獵) = 膚憲壓願窪糧觸淵蓋選獵淵願鹹繭淵鑰鑰選鑰 (艱餘鹹膚範網壓鹽膚憲, 夢築鏇簾簾範糧憲構網 ~ 構壓艱鹹艱蓋構簾齋齋) 更多